Trial Profile
A Randomized, Open-label Study to Assess the Safety and Tolerability of Multiple Dose Levels and Multiple Dosing Regimens of AT2101 in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Isofagomine tartrate (Primary)
- Indications Gaucher's disease type I
- Focus Adverse reactions
- Sponsors Amicus Therapeutics
- 20 May 2014 New trial record